SynthesisFrontiers in neurology2024

Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis of randomized trials.

Eoin Moloney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.